Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Cynata Therapeutics (CYP) shares

Learn how to easily invest in Cynata Therapeutics shares.

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.

A$0.57
current price
A$-0.03
change
-5%
change %

How to buy shares in Cynata Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Cynata Therapeutics. Find the share by name or ticker symbol: CYP. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Cynata Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At today's price of A$0.57, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Cynata Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Cynata Therapeutics. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Price details for Cynata Therapeutics (CYP)

Open A$0.595 Previous close A$0.6
High A$0.595 Change A$-0.03
Low A$0.565 Change % -5%
Close A$0.57 Timestamp 1642114800
Volume N/A GMT offset 0

Cynata Therapeutics stock price

Use our graph to track the performance of CYP stocks over time.

Cynata Therapeutics company summary

Information last updated 2022-01-16.

Cynata Therapeutics (CYP) is a leading Biotechnology business based in Australia. Cynata Therapeutics (CYP) is listed on the ASX and employs 0 staff.

Profile

Industry Biotechnology Currency symbol A$
Code CYP Country name Australia
Type Common Stock Country ISO AU
Name Cynata Therapeutics Limited ISIN AU000000CYP7
Exchange AU CUSIP N/A
Currency code AUD Sector Healthcare
Currency name Australian Dollar Full-time employees 0

Detailed company information

Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops CYP-004, which is in Phase III clinical trial used for the treatment of osteoarthritis; and products for the treatment of asthma, heart attack, diabetic wounds, coronary artery disease, acute respiratory distress syndrome, brain cancer, melanoma, sepsis, osteoarthritis, and critical limb ischemia, which are in a preclinical model. Cynata Therapeutics Limited has a strategic partnership with Fujifilm to provide clinical and commercial manufacturing services for, and supply of, Cynata's Cymerus therapeutic mesenchymal stem cell products. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was founded in 2011 and is based in Cremorne, Australia.

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More guides on Finder

Go to site